PHARMACEUTICAL COMPOSITION FOR THE INHIBITION OF LIPOGENESISCOMPRISING A REGULATOR OF PRP19 EXPRESSION

摘要

The downregulation of PRP 19 (precursor RNA processing 19) protein expressio n results in effectively reducing the expression of SCD1 (stearyl CoA desatura se- 1), the key lipogenic enzyme, and its down-stream triacylglycerol synthesis enzymes, DGAT-1 (diacyglycerol acyltransferase-1) and GPAT (glycerol-phospha te acyltransferase), as well as the intracellular content of neutral lipids, th e major target for treating obesity.